GLF
ATNM icon

Groupe la Francaise’s Actinium Pharmaceuticals ATNM Stock Holding History

Groupe la Francaise’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-316
Closed -$436 – 483
2025
Q3 		$436 Buy
+316
New +$515 ﹤0.01% 754

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Groupe la Francaise's ATNM Position: Q4 2025 in Review

Groupe la Francaise sold out of Actinium Pharmaceuticals (ATNM) in Q4 2025, closing a stake of 316 shares — an estimated $436 sold.

Groupe la Francaise first reported a position in ATNM in Q3 2025 and held it in 1 quarter. The position peaked at $436 in Q3 2025. 60 funds tracked by Wall St. Rank hold ATNM as of Q4 2025.

  • Groupe la Francaise reported no remaining Actinium Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Groupe la Francaise sold 316 Actinium Pharmaceuticals shares in Q4 2025, an estimated $436.
  • Groupe la Francaise first reported a position in Actinium Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Groupe la Francaise's Actinium Pharmaceuticals position peaked at $436 in Q3 2025.
  • 60 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.